Everolimus

Key Product Details

Product Description

Everolimus is a mTOR inhibitor. Inhibits tumor proliferation in vitro and in vivo. Inhibits VEGF-induced HUVEC proliferation in vitro, but does not affect tumor vascular permeability in mouse models. Immunosuppressant. Activates autophagy.

Product Specifications for Everolimus

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Everolimus

The following data is based on the product molecular weight 958.22.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.04 mL	5.22 mL	10.44 mL
5 mM	0.21 mL	1.04 mL	2.09 mL
10 mM	0.10 mL	0.52 mL	1.04 mL
50 mM	0.02 mL	0.10 mL	0.21 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 16 publications citing the usage of this product.

• Sedrani Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998 PMID: 9723437
• Galluzzi Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. 2017 PMID:  28529316
• Lane mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin.Cancer Res. 2009 PMID: 19223496

Product Documents for Everolimus